Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open Label Evaluation of the Single Dose Pharmacokinetics of Delafloxacin in Subjects With and Without Hepatic Impairment

Trial Profile

An Open Label Evaluation of the Single Dose Pharmacokinetics of Delafloxacin in Subjects With and Without Hepatic Impairment

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 17 Oct 2016

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Delafloxacin (Primary)
  • Indications Gonorrhoea; Methicillin-resistant Staphylococcus aureus infections; Skin and soft tissue infections
  • Focus Pharmacokinetics
  • Sponsors Melinta Therapeutics

Most Recent Events

  • 29 Aug 2016 Results published in the Journal of Clinical Pharmacology
  • 09 Oct 2015 Results of this trial were presented at ID Week, the annual meeting of both the Infectious Disease Society of America and the Society for Healthcare Epidemiology of America, according to a Melinta Therapeutics media release.
  • 29 Apr 2015 Status changed from recruiting to completed, as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top